Clinical Trial Update: A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion [Phase 1]

View source ↗

Summary

First-in-human Phase 1 trial evaluating the safety of infusing autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria in patients with pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Diseases

Drugs mentioned

• MNV-BM-PLC

Snippet

Sponsor: Minovia Therapeutics Ltd. | Conditions: Primary Mitochondrial Diseases | Phase 1 | Status: WITHDRAWN